Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

Risk of Secondary Hematological Malignancies in Patients with Follicular Lymphoma: A Retrospective Analysis of 1045 Patients Treated in the Rituximab Era

Roosa Enni Inkeri Prusila, Marc Sorigue, Aleksi Postila, Petteri Salmi, Taru Tanhua, Susanna Tikkanen, Sakari Kakko, Hanne Kuitunen, Marjukka Pollari, Ilja Nystrand, Milla Kuusisto, Kaija Vasala, Esa Jantunen, Eija Korkeila, Peeter Karihtala, Taina Turpeenniemi-Hujanen, Outi Kuittinen

Blood (2018) 132 (Supplement 1): 5330.

https://doi.org/10.1182/blood-2018-99-110129

Published: 2018

Journal Articles

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Riikka Räty, Tuomo Honkanen, Esa Jantunen, MDPhD, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Outi Kuittinen, Minna Lehto, Maija Mikkola, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, MD, Sanna Siitonen, Merja Suominen, MD, Mirja Vapaatalo, Erkki Elonen

Blood (2014) 124 (21): 1749.

https://doi.org/10.1182/blood.V124.21.1749.1749

Published: 2014

Journal Articles

Comparison of Post-Transplant Outcomes in Non-Hodgkin Lymphoma (NHL) Patients Mobilized with or without Plerixafor Added to Chemomobilization

Ville Varmavuo, Johanna Rimpiläinen, Anne Nihtinen, Kaija Vasala, Maija Mikkola, Päivi Lehtonen, Taru Kuittinen, Pentti Mäntymaa, Tapio Nousiainen, Outi Kuittinen, Esa Jantunen

Blood (2012) 120 (21): 4520.

https://doi.org/10.1182/blood.V120.21.4520.4520

Published: 2012

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Blood (2011) 118 (21): 331.

https://doi.org/10.1182/blood.V118.21.331.331

Published: 2011

Journal Articles

Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood (2010) 116 (21): 3565.

https://doi.org/10.1182/blood.V116.21.3565.3565

Published: 2010

Journal Articles

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood (2010) 116 (21): 3566.

https://doi.org/10.1182/blood.V116.21.3566.3566

Published: 2010

Journal Articles

Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report

Sigal Grisariu, Batia Avni, Tracy T. Batchelor, Martin J. van den Bent, Felix Bokstein, David Schiff, Outi Kuittinen, Marc C. Chamberlain, Patrick Roth, Anatoly Nemets, Edna Shalom, Dina Ben-Yehuda, Tali Siegal

Blood (2010) 115 (24): 5005–5011.

https://doi.org/10.1182/blood-2009-12-258210

Published: 2010

Journal Articles

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Blood (2010) 115 (8): 1530–1533.

https://doi.org/10.1182/blood-2009-08-236570

Published: 2010

Includes: Supplemental data

Journal Articles

Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group

Erkki Elonen, Riikka Räty, Tuomo Honkanen, Esa Jantunen, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, Outi Kuittinen, Minna Lehto, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, Sanna Siitonen, Merja Suominen, Mirja Vapaatalo

Blood (2008) 112 (11): 1001.

https://doi.org/10.1182/blood.V112.11.1001.1001

Published: 2008

Journal Articles

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Blood (2008) 112 (7): 2687–2693.

https://doi.org/10.1182/blood-2008-03-147025

Published: 2008

Journal Articles

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Blood (2007) 110 (11): LB1.

https://doi.org/10.1182/blood.V110.11.LB1.lb1

Published: 2007

Journal Articles

Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG).

Blood (2006) 108 (11): 401.

https://doi.org/10.1182/blood.V108.11.401.401

Published: 2006

NARROW

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Risk of Secondary Hematological Malignancies in Patients with Follicular Lymphoma: A Retrospective Analysis of 1045 Patients Treated in the Rituximab Era

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Comparison of Post-Transplant Outcomes in Non-Hodgkin Lymphoma (NHL) Patients Mobilized with or without Plerixafor Added to Chemomobilization

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only